A5083000448- Microbial Metabolic Engineering and Bioproduction
- Optimal Experimental Design Methods
- Advanced Multi-Objective Optimization Algorithms
- Statistical Methods in Clinical Trials
- Gene Regulatory Network Analysis
- Scientific Computing and Data Management
- Inflammasome and immune disorders
- Bioinformatics and Genomic Networks
- Receptor Mechanisms and Signaling
- Mathematical Biology Tumor Growth
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Complement system in diseases
- Cholesterol and Lipid Metabolism
- Sphingolipid Metabolism and Signaling
- Probabilistic and Robust Engineering Design
Novartis (Switzerland)
2023-2024
Inserm
2015-2018
Délégation Paris 7
2015-2018
Sorbonne Paris Cité
2015-2018
Université Paris Cité
2015-2018
Abstract This first‐in‐human study evaluated the safety, tolerability, single‐ and multiple‐dose pharmacokinetic profiles with dietary influence, pharmacodynamics (PD) of DFV890, an oral NLRP3 inhibitor, in healthy participants. In total, 122 participants were enrolled into a three‐part trial including single 2‐week multiple ascending doses (SAD MAD, respectively) randomized (3:1) to DFV890 or placebo [3–600 mg] MAD [fasted: 10–200 mg, once‐daily fed: 25 50 twice‐daily]). was generally...
The lack of a common exchange format for mathematical models in pharmacometrics has been long-standing problem. Such the potential to increase productivity and analysis quality, simplify handling complex workflows, ensure reproducibility research, facilitate reuse existing model resources. Pharmacometrics Markup Language (PharmML), currently under development by Drug Disease Model Resources (DDMoRe) consortium, is intended become an standard providing means encode models, trial designs,...
Recent work on Model Informed Drug Discovery and Development (MID3) has noted the need for clarity in model description used quantitative disciplines such as pharmacology statistics.1-3 Currently, models are encoded a variety of computer languages shared through publications that rarely include original code generally lack reproducibility. The DDMoRe Description Language (MDL) been developed primarily language standard to facilitate sharing knowledge understanding models. Models now not just...
Abstract Background and Aims Iptacopan (LNP023) is a first-in-class, oral, proximal complement inhibitor that specifically binds to Factor B inhibits the alternative pathway (AP). Current Phase III studies of iptacopan focus on diseases associated with AP activation, such as paroxysmal nocturnal hemoglobinuria (PNH), C3 glomerulonephritis (C3G), IgA nephropathy (IgAN), atypical hemolytic uremic syndrome. The liver primary route elimination. Based previous healthy volunteer pharmacokinetic...